Institute for Health Insurance, Faculty of Health Sciences, University of Pécs, Pécs, Hungary.
Doctoral School of Health Sciences, Faculty of Health Sciences, University of Pécs, Pécs, Hungary.
BMC Musculoskelet Disord. 2024 May 23;25(1):406. doi: 10.1186/s12891-024-07513-y.
Health services utilization related to hip osteoarthritis imposes a significant burden on society and health care systems. Our aim was to analyse the epidemiological and health insurance disease burden of hip osteoarthritis in Hungary based on nationwide data.
Data were extracted from the nationwide financial database of the National Health Insurance Fund Administration (NHIFA) of Hungary for the year 2018. The analysed data included annual patient numbers, prevalence, and age-standardized prevalence per 100,000 population in outpatient care, health insurance costs calculated for age groups and sexes for all types of care. Patients with hip osteoarthritis were identified using code M16 of the International Classification of Diseases (ICD), 10th revision. Age-standardised prevalence rates were calculated using the European Standard Population 2013 (ESP2013).
Based on patient numbers of outpatient care, the prevalence per 100,000 among males was 1,483.7 patients (1.5%), among females 2,905.5 (2.9%), in total 2,226.2 patients (2.2%). The age-standardised prevalence was 1,734.8 (1.7%) for males and 2,594.8 (2.6%) for females per 100,000 population, for a total of 2,237.6 (2.2%). The prevalence per 100,000 population was higher for women in all age groups. In age group 30-39, 40-49, 50-59, 60-69 and 70 + the overall prevalence was 0.2%, 0.8%, 2.7%, 5.0% and 7.7%, respectively, describing a continuously increasing trend. In 2018, the NHIFA spent 42.31 million EUR on the treatment of hip osteoarthritis. Hip osteoarthritis accounts for 1% of total nationwide health insurance expenditures. 36.8% of costs were attributed to the treatment of male patients, and 63.2% to female patients. Acute inpatient care, outpatient care and chronic and rehabilitation inpatient care were the main cost drivers, accounting for 62.7%, 14.6% and 8.2% of the total health care expenditure for men, and 51.0%, 20.0% and 11.2% for women, respectively. The average annual treatment cost per patient was 3,627 EUR for men and 4,194 EUR for women.
The prevalence of hip osteoarthritis was 1.96 times higher (the age-standardised prevalence was 1.5 times higher) in women compared to men. Acute inpatient care was the major cost driver in the treatment of hip osteoarthritis. The average annual treatment cost per patient was 15.6% higher for women compared to men.
髋关节骨关节炎相关的卫生服务利用给社会和医疗保健系统带来了巨大负担。我们的目的是基于全国数据分析匈牙利髋关节骨关节炎的流行病学和医疗保险疾病负担。
数据从匈牙利国家健康保险基金管理局（NHIFA）的全国财务数据库中提取，分析数据包括 2018 年门诊患者数量、患病率以及每 10 万人中年龄标准化的患病率，按年龄组和性别计算了所有类型护理的医疗保险费用。使用国际疾病分类（ICD）第 10 版的 M16 代码识别髋关节骨关节炎患者。使用欧洲标准人口 2013（ESP2013）计算年龄标准化患病率。
根据门诊护理患者数量，男性每 10 万人的患病率为 1,483.7 例（1.5%），女性为 2,905.5 例（2.9%），总计为 2,226.2 例（2.2%）。年龄标准化患病率为男性每 10 万人 1,734.8 例（1.7%），女性为 2,594.8 例（2.6%），总计为 2,237.6 例（2.2%）。在所有年龄组中，女性的患病率都高于男性。在 30-39 岁、40-49 岁、50-59 岁、60-69 岁和 70 岁及以上年龄组中，总体患病率分别为 0.2%、0.8%、2.7%、5.0%和 7.7%，呈持续上升趋势。2018 年，NHIFA 用于髋关节骨关节炎治疗的费用为 4231 万欧元。髋关节骨关节炎占全国医疗保险总支出的 1%。36.8%的费用归因于男性患者的治疗，63.2%归因于女性患者。急性住院治疗、门诊治疗和慢性及康复住院治疗是主要的费用驱动因素，分别占男性总医疗费用的 62.7%、14.6%和 8.2%，占女性的 51.0%、20.0%和 11.2%。每位患者的平均年治疗费用为男性 3627 欧元，女性 4194 欧元。
女性髋关节骨关节炎的患病率（年龄标准化患病率）是男性的 1.96 倍（1.5 倍）。急性住院治疗是髋关节骨关节炎治疗的主要费用驱动因素。每位女性患者的平均年治疗费用比男性高 15.6%。
